Dyspnea, commonly known as breathlessness, is a frequent clinical presentation in both inpatient and outpatient settings. The etiology of dyspnea is multifactorial, often making diagnosis and management challenging. This article aims to provide a comprehensive clinical approach to dyspnea.
Dyspnea may be the result of cardiac, respiratory, neuromuscular, psychogenic, or metabolic disorders. A detailed history and physical examination are crucial initial steps. These should focus on the onset, duration, and exacerbating or relieving factors of the breathlessness. Associated symptoms such as cough, chest pain, and orthopnea can provide clues to the underlying cause.
Diagnostic evaluation should be guided by the clinical suspicion. Basic investigations include complete blood count, chest X-ray, and electrocardiogram. Pulmonary function tests can assess the degree of airflow obstruction. If cardiac etiology is suspected, echocardiography and cardiac stress tests may be warranted. In uncertain cases, CT scan or bronchoscopy may be necessary.
The management of dyspnea should be directed towards the underlying cause. For instance, in patients with COPD, bronchodilators and steroids may be beneficial. Patients with heart failure may require diuretics, beta-blockers, and ACE inhibitors. Non-pharmacological interventions such as pulmonary rehabilitation and breathing exercises can also be beneficial. In palliative care settings, opioids may be used to alleviate breathlessness.
Understanding the multifactorial nature of dyspnea is key to its effective management. A systematic approach, including detailed history, physical examination, and appropriate investigations, can help identify the underlying cause. Tailored management strategies can then be implemented to provide symptomatic relief and improve quality of life. Continued research is needed to further refine our understanding and approach to the breathless patient.
1.
Prostate cancer detection with PET CT and PET MRI is comparable.
2.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
3.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
4.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
5.
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
3.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
4.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
5.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Thromboprophylaxis In Medical Settings
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation